| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
AEGON NV 2017 Q1 - Results - Earnings Call Slides
https://seekingalpha.com/article/4072122-aegon-nv-2017-q1-results-earnings-call-slides?source=feed_sector_financial
May 11, 2017 - The following slide deck was published by AEGON NV in conjunction with their 2017 Q1 earnings call.
1
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
https://www.fool.com/investing/2017/09/05/gilead-sciences-couldnt-have-timed-its-splash-into.aspx?source=iedfolrf0000001
Sep 05, 2017 - The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
1
5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition
https://www.fool.com/investing/2017/09/11/5-tough-questions-for-gilead-sciences-about-the-ki.aspx?source=iedfolrf0000001
Sep 11, 2017 - Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move.
1
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout
https://www.fool.com/investing/2018/01/27/3-reasons-why-the-juno-thearapeutics-buyout-makes.aspx?source=iedfolrf0000001
Jan 27, 2018 - Right product, right price, right time. What more can you ask for?
1
TomTom NV (TMOAF) CEO Harold Goddijn on Q2 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4187787-tomtom-nv-tmoaf-ceo-harold-goddijn-q2-2018-results-earnings-call-transcript?source=feed_all_articles
Jul 17, 2018 - TomTom NV (OTCPK:TMOAF) Q2 2018 Earnings Conference Call July 17, 2018, 08:00 ET Executives Bruno Priuli - IR Harold Goddijn - Co-Founder, Chairman & CEO Taco Titulaer - CFO Analysts Francois Bouv
1
QUAD GRAPHICS (QUAD) - Profit Tracks
http://www.zacks.com/research/screening/tracks/highlight.php?id=4948&cid=CS-ZC--4948
Apr 26, 2012 - QUAD GRAPHICS
0
Novartis' (NVS) Promacta Label Further Expanded in U.S.
http://www.zacks.com/stock/news/187863/novartis-nvs-promacta-label-further-expanded-in-us?cid=CS-ZC-FT-187863
Aug 26, 2015 - Novartis (NVS) with partner Ligand (LGND) announced that the FDA has approved the use of Promacta in children between 1 to 6 years of age with chronic ITP.
0
Novartis' Farydak Gets EU Approval for Multiple Myeloma
http://www.zacks.com/stock/news/189134/novartis-farydak-gets-eu-approval-for-multiple-myeloma?cid=CS-ZC-FT-189134
Sep 07, 2015 - Novartis' (NVS) Farydak (plus Velcade and dexamethasone) gets EU approval for relapsed and/or refractory multiple myeloma in treatment-experienced patients.
0
Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer
http://www.zacks.com/stock/news/189800/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer?cid=CS-ZC-FT-189800
Sep 11, 2015 - Aduro (ADRO) signed a clinical study agreement with Incyte (INCY) to evaluate CRS-207, in combination with Incyte's epacadostat, in patients with ovarian cancer.
0
Mylan NV Presents at Morgan Stanley Healthcare Brokers Conference (Transcript)
http://seekingalpha.com/article/3518926-mylan-nv-presents-at-morgan-stanley-healthcare-brokers-conference-transcript?source=feed_tag_transcripts
Sep 17, 2015 - Mylan NV (NASDAQ:MYL) Morgan Stanley Healthcare Conference Call September 17, 2015 2:40 PM ET Executives Heather Bresch - Chief Executive Officer John Sheehan - CFO, EVP, Principal Financial & Acc
0